Yes, I don't think much has changed in the 3-month period since the last time you asked that, Rich. I think our thinking is still the same. We did increase, as I mentioned in my prepared remarks, our buyback authorization, to $500 million. I think you'll continue to see us return capital via that vehicle. We do believe that there still is a lot of growth opportunity in this space. You saw it with the WhenTech acquisition, you saw it with the announcement of our intention to acquire a controlling share in APX-ENDEX. So -- and in addition to the growth opportunities, there are still some uncertainties. The same ones that we talked about last time. There are tax quality questions that are left to be unanswered or that are left to be answered, in addition to a number of other questions like regulatory capital. As Jeff mentioned, we don't expect those regulatory capital requirements will materially alter the strength of our balance sheet or materially alter our P&L in any way, but as we sit here today, the items of uncertainty that we talked about last time and our view that there's a lot of growth opportunity left in this space, really hasn't changed. But I'll close as I did last time. This is something we spend a lot of time thinking about internally, something we talked about with our board as recently as September and something that we feature with them at each of our board meetings during the year. So we'll continue to look at it, but I do think the kind of headline is, lots of opportunity to grow, and as long as we think we can do that and generate the kinds of returns we've done historically, we're going to continue to make those investments.
Richard H. Repetto - Sandler O'Neill + Partners, L.P., Research Division: Okay. That's helpful. And then Jeff, you talked about Creditex potentially being a SEF. And, I guess, the question is why doesn't ICE just -- do you need to be a SEF at Creditex? Your former partner, [indiscernible], they got a DCM license and they're going to be trading swaps with just the exchange license. So I guess, yes, the question is you've got the, now, the index futures products and CDS, why doesn't ICE, just itself, go more aggressively on the over-the-counter side?